Also found in: Medical, Wikipedia.
CD38Cluster of Differentiation 38 (glycoprotein)
References in periodicals archive ?
Interference with Serological Testing - Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Coombs test).
With the approval of daratumumab, a new antibody option targeting CD38, along with ongoing work to advance the development of novel classes of therapies by both Janssen and MMRF, we are ushering in a new era of myeloma therapy focused on individualized treatment approaches for patients with significant unmet needs.
Daratumumab is an investigational human monoclonal antibody that binds with high affinity to the CD38 molecule, which is found on the surface of multiple myeloma cells.
Clinicopathologic data were collected retrospectively from the medical records and included (1) BM status, including plasma cell percentage and presence or absence of plasmablastic morphology; (2) biochemical markers, including serum [beta]2-microglobulin, creatinine, immunoglobulin (such as IgG, IgA, IgM), serum calcium, and urine protein levels; (3) bone lesions; (4) therapy and response, including chemotherapeutic agents, relapse, and refractoriness to therapy; and (5) immunophenotypic markers, including expression assessment of cytoplasmic immunoglobulin light chains ([lambda] and [kappa]), CD20, CD38, CD56, CD138.
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Immunophenotyping of bone marrow aspirate was performed using CD45, CD19, CD56, and CD38 (a limited panel of markers was used due to financial constraints).
In this study, the level of CD38 expression, above which CD8 T cells were defined as activated, was not clearly stated.
Poor recovery of CD4+ T cells in HIV patients on ART correlates with elevated expression of CD38, HLA-DR, Ki67 and CD57 on T cells [6,17,26,27] and increased rates of CD4+ T cell turnover [25].
peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Markers recently demonstrated to be of value are the mutation status of the genes of the variable region of the immunoglobulin heavy chain (IGHV) and the expression of CD38 and ZAP70 [[zeta]-chain (TCR) associated protein kinase 70kDa].
In addition to antiviral activity and safety, several immune markers were assessed, including the surface activation markers, CD38 and HLA-DR; Ki-67, a cell surface protein indicative of cell replication; and PD-1, a marker of cell exhaustion after chronic activation.